Iron overload and apoptosis of HL-1 cardiomyocytes: Effects of calcium channel blockade

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Chen, Mei Pian ^a   Cabantchik, Z Ioav ^b   Chan, Shing ^a   Chan, Godfrey Chi Fung ^a   Cheung, Yiu Fai ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CASPASE 3; IRON; LIPOCORTIN 5; CALCIUM; FERRIC ION;

APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL CULTURE; CELL DAMAGE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HEART; HEART MUSCLE CELL; HEMOSIDEROSIS; IRON OVERLOAD; IRON TRANSPORT; QUANTITATIVE ANALYSIS; SENSOR; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; MITOCHONDRION; MOUSE;

ANIMALS; APOPTOSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOMYOPATHIES; CASPASE 3; CELL LINE; FERRIC COMPOUNDS; HEART; IRON; IRON OVERLOAD; MICE; MITOCHONDRIA; MYOCYTES, CARDIAC;

EID: 84911442423     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112915     Document Type: Article

References (63)

1. Lieu PT, Heiskala M, Peterson PA, Yang Y (2001) The roles of iron in health and disease. Mol Aspects Med 22: 1-87.
2. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, et al. (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102: 2670-2677.
3. Hershko CM, Link GM, Konijn AM, Cabantchik ZI (2005) Iron chelation therapy. Curr Hematol Rep 4: 110-116.
4. Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, et al. (2004) Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 109: 1877-1885.
5. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y (2010) Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 56: 1001-1012.
6. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK (1995) Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation 91: 66-71.
7. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, et al. (1999) Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation 100: 2074-2078.
8. Muhlestein JB (2000) Cardiac abnormalities in hemochromatosis. In: Barton JC, Edwards CQ, editors. Hemochromatosis: genetics, pathophysiology, diagnosis, and treatment Cambridge University Press. pp. 297-310.
9. Murphy CJ, Oudit GY (2010) Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16: 888-900.
10. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, et al. (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331: 574-578.
11. Horwitz LD, Rosenthal EA (1999) Iron-mediated cardiovascular injury. Vasc Med 4: 93-99.
12. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, et al. (1996) Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189.
13. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, et al. (1997) Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141.
14. Kang PM, Izumo S (2000) Apoptosis and heart failure: A critical review of the literature. Circ Res 86: 1107-1113.
15. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497-1504.
16. Foo RS, Mani K, Kitsis RN (2005) Death begets failure in the heart. J Clin Invest 115: 565-571.
17. Lee Y, Gustafsson AB (2009) Role of apoptosis in cardiovascular disease. Apoptosis 14: 536-548.
18. Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117: 285-297.
19. Chattipakorn N, Kumfu S, Fucharoen S, Chattipakorn S (2011) Calcium channels and iron uptake into the heart. World J Cardiol 3: 215-218.
20. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, et al. (2003) L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in ironoverload cardiomyopathy. Nat Med 9: 1187-1194.
21. Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH (2006) Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl) 84: 349-364.
22. Tsushima RG, Wickenden AD, Bouchard RA, Oudit GY, Liu PP, et al. (1999) Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Circ Res 84: 1302-1309.
23. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N (2012) Ttype calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol 88: 535-548.
24. Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, et al. (2011) T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 86: 156-166.
25. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
26. White SM, Constantin PE, Claycomb WC (2004) Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 286: H823-829.
27. Xia M, Salata JJ, Figueroa DJ, Lawlor AM, Liang HA, et al. (2004) Functional expression of L- and T-type Ca2+ channels in murine HL-1 cells. J Mol Cell Cardiol 36: 111-119.
28. Parkes JG, Olivieri NF, Templeton DM (1997) Characterization of Fe2+ and Fe3 + transport by iron-loaded cardiac myocytes. Toxicology 117: 141-151.
29. Randell EW, Parkes JG, Olivieri NF, Templeton DM (1994) Uptake of non-transferrin- bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 269: 16046-16053.
30. Glickstein H, El RB, Shvartsman M, Cabantchik ZI (2005) Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106: 3242-3250.
31. Lecoeur H, Melki MT, Saidi H, Gougeon ML (2008) Analysis of apoptotic pathways by multiparametric flow cytometry: application to HIV infection. Methods Enzymol 442: 51-82.
32. Oancea M, Mazumder S, Crosby ME, Almasan A (2006) Apoptosis assays. Methods Mol Med 129: 279-290.
33. Kontoghiorghes GJ (2006) Iron mobilization from transferrin and non-transferrin- bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 30: 183-200.
34. Nday CM, Malollari G, Petanidis S, Salifoglou A (2012) In vitro neurotoxic Fe(III) and Fe(III)-chelator activities in rat hippocampal cultures. From neurotoxicity to neuroprotection prospects. J Inorg Biochem 117: 342-350.
35. Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, et al. (2011) Iron-induced cardiac damage: role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 336: 56-63.
36. Munoz JP, Chiong M, Garcia L, Troncoso R, Toro B, et al. (2010) Iron induces protection and necrosis in cultured cardiomyocytes: Role of reactive oxygen species and nitric oxide. Free Radic Biol Med 48: 526-534.
37. Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72: 19-44.
38. Shvartsman M, Kikkeri R, Shanzer A, Cabantchik ZI (2007) Non-transferrinbound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol 293: C1383-1394.
39. Catterall WA, Striessnig J (1992) Receptor sites for Ca2 + channel antagonists. Trends Pharmacol Sci 13: 256-262.
40. Winegar BD, Kelly R, Lansman JB (1991) Block of current through single calcium channels by Fe, Co, and Ni. Location of the transition metal binding site in the pore. J Gen Physiol 97: 351-367.
41. Atar D, Backx PH, Appel MM, Gao WD, Marban E (1995) Excitationtranscription coupling mediated by zinc influx through voltage-dependent calcium channels. J Biol Chem 270: 2473-2477.
42. Hamann SR, Blouin RA, McAllister RG Jr (1984) Clinical pharmacokinetics of verapamil. Clin Pharmacokinet 9: 26-41.
43. Mak IT, Weglicki WB (1990) Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1452.
44. Lansman JB, Hess P, Tsien RW (1986) Blockade of current through single calcium channels by Cd2+, Mg2+, and Ca2+ . Voltage and concentration dependence of calcium entry into the pore. J Gen Physiol 88: 321-347.
45. Rosa JM, Nanclares C, Orozco A, Colmena I, de Pascual R, et al. (2012) Regulation by L-Type Calcium Channels of Endocytosis: An Overview. J Mol Neurosci.
46. Sohn YS, Ghoti H, Breuer W, Rachmilewitz E, Attar S, et al. (2012) The role of endocytic pathways in cellular uptake of plasma non-transferrin iron. Haematologica 97: 670-678.
47. Yasui K, Niwa N, Takemura H, Opthof T, Muto T, et al. (2005) Pathophysiological significance of T-type Ca2+ channels: expression of T-type Ca2+ channels in fetal and diseased heart. J Pharmacol Sci 99: 205-210.
48. Martinez ML, Heredia MP, Delgado C (1999) Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 31: 1617-1625.
49. Huang B, Qin D, Deng L, Boutjdir M, Nabil ES (2000) Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 46: 442-449.
50. Li W, Coates T, Wood JC (2008) Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. Haematologica 93: 311-312.
51. Kolnagou A, Kleanthous M, Kontoghiorghes GJ (2011) Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin 35: 186-198.
52. Grandi E, Pandit SV, Voigt N, Workman AJ, Dobrev D, et al. (2011) Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res 109: 1055-1066.
53. Shvartsman M, Fibach E, Cabantchik ZI (2010) Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Biochem J 429: 185-193.
54. Shvartsman M, Ioav Cabantchik Z (2012) Intracellular iron trafficking: role of cytosolic ligands. Biometals 25: 711-723.
55. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, et al. (2011) Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis 2: e244.
56. Wang T, Hu N, Cao J, Wu J, Su K, et al. (2013) A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating. Biosens Bioelectron 49: 9-13.
57. Jonsson MK, Wang QD, Becker B (2011) Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev Technol 9: 589-599.
58. Rao F, Deng CY, Wu SL, Xiao DZ, Huang W, et al. (2013) Mechanism of macrophage migration inhibitory factor-induced decrease of T-type Ca(2+) channel current in atrium-derived cells. Exp Physiol 98: 172-182.
59. Lu WY, Zhao MF, Chai X, Meng JX, Zhao N, et al. (2013) [Reactive oxygen species mediate the injury and deficient hematopoietic supportive capacity of umbilical cord derived mesenchymal stem cells induced by iron overload]. Zhonghua Yi Xue Za Zhi 93: 930-934.
60. Lu WY, Zhao MF, Sajin R, Zhao N, Xie F, et al. (2013) [Effect and mechanism of iron-catalyzed oxidative stress on mesenchymal stem cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 35: 6-12.
61. Dai J, Huang C, Wu J, Yang C, Frenkel K, et al. (2004) Iron-induced interleukin-6 gene expression: possible mediation through the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. Toxicology 203: 199-209.
62. Salvador GA, Oteiza PI (2011) Iron overload triggers redox-sensitive signals in human IMR-32 neuroblastoma cells. Neurotoxicology 32: 75-82.
63. Al-Rousan RM, Paturi S, Laurino JP, Kakarla SK, Gutta AK, et al. (2009) Deferasirox removes cardiac iron and attenuates oxidative stress in the ironoverloaded gerbil. Am J Hematol 84: 565-570.